Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.2 mg to 120 mg Administered by Intravenous Infusion and 40 mg to 120 mg Administered by Subcutaneous Injection) of BI 655064 (Buffer Solution for Injection) in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)
Latest Information Update: 20 Nov 2017
Price :
$35 *
At a glance
- Drugs BI 655064 (Primary) ; BI 655064 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Nov 2017 Results published in the European Journal of Clinical Pharmacology
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 14 Jan 2013 New trial record